Development and validation of a solid-phase extraction and high-performance liquid chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe (SR-4554) in Balb/c mouse plasma.
N-(2-Hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide, a novel 2-nitroimidazole, is currently being developed as a non-invasive probe for tumour hypoxia. A sensitive (minimum quantifiable level = 25 ng/ml; C.V. = 6.01%) and selective assay has, therefore, been developed for the analysis of this compound in mouse plasma. The assay employed a solid-phase extraction followed by a rapid (10 min) HPLC analysis with UV-photodiode-array detection. No drug-related metabolites were observed in plasma when mice were treated with 180 mg/kg of the drug. The assay has proved to be suitable for studying the plasma pharmacokinetics of this fluorinated 2-nitroimidazole in mice.
Aboagye
E O
EO
CRC Department of Medical Oncology, University of Glasgow, CRC Beatson Laboratories, UK.
Graham
M A
MA
Lewis
A D
AD
Workman
P
P
Kelson
A B
AB
Tracy
M
M
D000818:Animals; D002138:Calibration; D015687:Cell Hypoxia; D002851:Chromatography, High Pressure Liquid; D005260:Female; D007202:Indicators and Reagents; D013058:Mass Spectrometry; D051379:Mice; D008807:Mice, Inbred BALB C; D015335:Molecular Probes / Q000097:blood* / Q000493:pharmacokinetics; D009593:Nitroimidazoles / Q000097:blood* / Q000493:pharmacokinetics; D011786:Quality Control; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D007202:Indicators and Reagents; D015335:Molecular Probes; D009593:Nitroimidazoles; C095171:SR 4554